Chinese scientists have used CRISPR Therapeutics (Nasdaq: CRSP) technology to genetically engineer cells in 86 cancer and HIV patients. The stock price leaped $5.03 to close at $38.78.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|